Other languages Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
3.46 ^USD	+2.98%		+21.40%	+49.14%

Mar. 20	North American Morning Briefing : Markets on Hold -2-	DJ
Mar. 19	JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mersana Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
Mersana Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28
Mersana Therapeutics Gears Up for Milestones in Cancer Drug Trials	Jan. 05
Mersana Therapeutics, Inc. Announces Business Updates	Jan. 05
Mersana Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
Mersana Therapeutics, Inc. Announces FDA Has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056	23-10-31
Mersana Therapeutics Names Martin Huber as Chief Executive	23-09-06
Mersana Therapeutics Announces Management Changes	23-09-06
Mersana Therapeutics, Inc. Announces Chief Executive Officer Changes	23-09-06
Mersana Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
Mersana Therapeutics Shares Plummet After Analyst Downgrades, Ovarian-Cancer Therapy Failure	23-07-27
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	23-07-27
Sector Update: Health Care	23-07-27
Mersana Therapeutics Says Trial of Ovarian Cancer Treatment Misses Primary Endpoint; Shares Plunge	23-07-27
Top Premarket Decliners	23-07-27
Mersana Therapeutics, Inc. Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization	23-07-27
BB Biotech dimezza la perdita trimestrale e dice addio a Piazza Affari	23-07-21
Top Midday Decliners	23-06-15
Mersana Therapeutics Says FDA Issues Partial Clinical Hold on Enrollment in Ovarian Cancer Drug Trials; Shares Plunge	23-06-15
Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials	23-06-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Other languages

Filters